A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1012600 Ophthalmic Solution 0.002% Compared With Latanoprost 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (Angel-J1 Study)
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Sepetaprost (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms Angel-J1 Study
- Sponsors Santen Pharmaceutical
Most Recent Events
- 03 Dec 2023 Status changed from recruiting to completed.
- 16 Aug 2022 New trial record